Introduction {#sec1-1}
============

Keloid is an overactive condition of the skin tissue to early lesions characterised by proliferation of fibroblasts and excessive production of collagen in the lesion, with mechanisms not yet fully understood \[[@ref1]\]. Areas most frequently affected are chest, shoulder, ear lobe. Keloid is usually itchy and painful \[[@ref2]\]. Nowadays, therapy is a challenge although many treatments are recommended, without agreement on the effectiveness of different choice. Bleomycin-induced apoptosis with sclerosing action on endothelial cells inhibited collagen synthesis by inhibiting the lysyl-oxidase enzyme and TGF-β, and it was used in keloid treatment for the first time by Bodokh and Brun in 1996 \[[@ref3]\].

We aimed to evaluate the efficacy of bleomycin injected in the injury for keloids treatment.

Methods {#sec1-2}
=======

A group of 55 patients with 120 studied scars were selected (aged from 15 to 70 years). Scar duration varies from several months to years, not been treated before, not ulcerated or infected.

An injectable solution of bleomycin was prepared by diluting 15 units of bleomycin in 10 ml of sterile saline. The medication was injected into the mid-lesion in depth, 0.2-0.4 ml/cm^2^ (maximum volume per session 3.5 ml). The interval between injections was 4 weeks, and the total number of treatment sessions depended on the cosmetic outcome of each lesion. Patients received chest X-ray before treatment every 3 months and 6 months after the last treatment.

Evaluation of the treatment response is conducted by VSS (Vancouver Scar Scale).

Results {#sec1-3}
=======

The average number of injections was 3.9 ± 1.1. After treatment, 80.8% of patients got itchiness relief, and 73.3% of patients got pain relief. Blood vessel status, scar stiffness, and scar thickness improved at 70.6%, 89.3% and 87%, respectively, by the VSS scale. In particular: 70.8% of scars became completely flat, 8.3% fairly flat, 17.5% comparatively flat, 3.3% averagely flat and no poorly flat scars.

Regarding undesirable effects, this study showed that 100% scar tissue lasted on average of 3.6 ± 1.4, 94/120 scars accounted for 78.3% have blisters, with an average length of 4.5 ± 1.3; 5.8% of ulcer scars with an average length of 10.6 ± 1.3; Hyperpigmentation was frequently noted after therapy (56.7%) and much thicker and harder the scar was, more treatment times was needed, with stiffness improvement poorer than in the treatment of soft and thin ones. The condition of vascular, pigmentation, and scar location had no relationship to some treatment as well as the level of scar thickness improvement as presented in [Table 1](#T1){ref-type="table"}.

###### 

Efficacy of the treatment

  Variable                         Value                       
  -------------------------------- -------------- ------------ ---------
  Vascularity                      1.7 ± 1        0.5 ± 0.6    \< 0.05
  Pigmentation                     0.2 ± 0.6      1.1 ± 1      
  Pliability                       2.8 ± 0.9      0.3 ± 0.5    
  Height                           2.3 ± 0.6      0.3 ± 0.5    
  Functional Symptoms                                          
   Pruritus                        80.8%                       
   Pain                            73.3%                       
  Scar thickness improvement                                   
   The complete flattening         70.8%                       
   Highly significant flattening   8.3%                        
   Significant flattening          17.5%                       
   Moderate flattening             3.3%                        
   Minimal flattening              0%                          
  Local side-effect                Lasting days                
   Pain                            120 (100%)     3.6 ± 1.4    
   Swollen                         26 (21.7%)     3.3 ± 1.2    
   Blisters                        94 (78.3%)     4.5 ± 1.3    
   Ulceration                      7 (5.8%)       10.6 ± 1.3   
   Scaled                          101 (84.1%)    13.6 ± 1.7   
   Hyperpigmentation               68 (56.7%)                  
  Recurrence                                                   
   After 3 months (n = 32)         0                           
   After 6 months (n = 26)         1 (3.8%)                    
   After 12 months (n = 13)        2 (15.4%                    
   After 15 months (n = 11)        5 (45.5%)                   
   After 18 months (n = 6)         3 (50%)                     

Due to many technical and financial constraints, our study did not measure bleomycin concentrations in the blood. However, in surveying complete blood count, liver and kidney function and chest X-ray, we did not record any systemic side effect. Local side effects were noted significantly, with 100% scars with pain during treatment.

Discussion {#sec1-4}
==========

We found that bleomycin improved vascular condition by 70.6% after treatment (mean VSS score from 1.7 ± 1 to 0.5 ± 0.6) and mean VSS of stiffness decreased by 89.3%. Some injections needed, itch and pain relief was similar to Saray et al., and S. Srivastava et al., studies \[[@ref4]\], \[[@ref5]\], \[[@ref6]\].

The recurrence rate in our study was higher than in Saray (2005), with 14% of patients recurring after 18 months \[[@ref4]\]. We found that the rate of recurrent scars in the thorax, the front of the breastbone was higher than in other surgical areas. The difference is statistically significant. In contrast, there was no relation between pre-treatment thickness and recurrence risk.

In conclusion, bleomycin is a safe and effective method for treating keloids. However, the high rate of recurrence after treatment confirms the difficulty in the correct management of keloid scars.
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